Clinical Trials Browser

Phase EARLY_PHASE1 × aldesleukin × 90 days × Clear all

NCT05493566 2026-02-12

Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Phase EARLY_PHASE1 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms